脑脊液血红素结合蛋白作为自发性脑出血后继发性脓毒症及院内结局的候选生物标志物:一项探索性转化蛋白质组学研究
本研究将大鼠脑出血+盲肠结扎穿刺双打击蛋白质组学模型与回顾性临床脑脊液队列(成人首次自发性脑出血,n=41)整合,用ELISA定量CSF-HPX。临床队列中CSF-HPX与血肿体积正相关,继发脓毒症组高于非脓毒症组(558.17 vs 305.99 ng/mL,p=0.006),校正后OR 1.016(95%CI 1.002-1.031;p=0.023),AUC 0.888。CSF-HPX升高亦与院内死亡相关但需谨慎解读;作者结论为探索性,需更大前瞻性研究验证。
要点
- 在成人首次自发性脑出血术后24 h内经脑室外引流留取脑脊液的回顾性队列(n=41)中,继发脓毒症者CSF-HPX中位数558.17 ng/mL,高于未继发者的305.99 ng/mL(p=0.006)。
- CSF-HPX与继发性脓毒症的关联在校正后仍显著(校正OR 1.016,95%CI 1.002-1.031;p=0.023),探索性判别AUC为0.888,但原文强调需前瞻性验证,不能据此设临床阈值。
- CSF-HPX与血肿体积呈正相关;CSF-HPX较高亦与院内死亡相关,原文明确该发现应谨慎解读。
- 动物模型中,ICH+CLP较单纯ICH早期生存更差(log-rank χ2=12.25,p=0.0005),HPX被鉴定为与出血-脓毒症复合状态相关的候选蛋白。
- 继发性脓毒症采用操作性Sepsis-3框架判定,且需排除入院时已存在感染或脓毒症者。
适用人群与场景
- 临床队列为成人首次自发性脑出血患者,术后24 h内经常规脑室外引流留取脑脊液(n=41)。
- 继发性脓毒症判定前排除入院时已存在感染或脓毒症者。
- 原文未提及院前或单纯ICU场景的适用人群,亦未列出其他纳入/排除标准。
诊断标准与关键阈值
- 继发性脓毒症采用操作性Sepsis-3框架判定,并排除入院时已存在感染或脓毒症者。
- CSF-HPX与GC/VDBP用ELISA定量;原文未给出诊断阈值或启动/停止阈值。
处置流程与药物剂量
- 原文为生物标志物探索性研究,未给出基于CSF-HPX的处置流程或药物剂量方案。
红旗征与不能漏的情况
- 原文未提及具体的红旗征或需立刻处理的临床情况。
研究设计与关键结果
- 研究类型:大鼠双打击(自体血诱导ICH后6 h行CLP,24 h取脑可溶性蛋白行iTRAQ LC-MS/MS)探索性蛋白质组学模型+回顾性临床CSF队列(n=41,单中心,原文未给出中心数)。
- 动物模型:ICH+CLP较单纯ICH早期生存更差(log-rank χ2=12.25,p=0.0005),HPX被鉴定为与出血-脓毒症复合状态相关的候选蛋白。
- 临床队列:CSF-HPX与血肿体积正相关;继发脓毒症组CSF-HPX 558.17(279.48-773.39)ng/mL vs 非脓毒症组305.99(218.77-354.24)ng/mL,p=0.006。
- 校正后OR 1.016(95%CI 1.002-1.031;p=0.023);探索性判别继发脓毒症AUC 0.888。
- CSF-HPX升高亦与院内死亡相关,原文注明应谨慎解读;原文未报告关键次要终点细节及不良事件。
证据类型、等级与局限
- 证据类型:探索性转化研究(动物蛋白质组学模型+回顾性临床队列),非RCT。
- 局限:作者明确为探索性发现,需更大前瞻性研究验证;临床队列为回顾性、样本小(n=41)、单中心、脑脊液经术后常规外引流获取。
对床旁实践的改变
- 原文为探索性生物标志物研究,尚不能改变急诊/ICU对脑出血后继发脓毒症的筛查或处置常规。
- 适用人群限于成人首次自发性脑出血且术后24 h内已留置脑室外引流者;不适用于未行脑室外引流或非首次自发性脑出血者(原文未提及这些人群)。
- 常见陷阱:将探索性AUC 0.888或校正OR 1.016误作临床决策阈值;CSF-HPX与院内死亡的关联原文要求谨慎解读。
指南或共识出处
- 原文未提及指南或共识名称;来源为PubMed收录的Neurocrit Care研究论文。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Secondary sepsis is a frequent and clinically important complication after spontaneous intracerebral hemorrhage (ICH), but biomarkers linking hemorrhage-related heme stress to subsequent systemic complications remain poorly defined. We investigated cerebrospinal fluid hemopexin (CSF-HPX) as a candidate biomarker associated with hemorrhage burden, secondary sepsis, and in-hospital outcome after ICH.
METHODS: We integrated a 2-hit exploratory animal proteomics model with a retrospective clinical CSF cohort. In rats, autologous blood-induced ICH was followed 6 h later by cecal ligation and puncture (CLP), and soluble brain proteins collected at 24 h were analyzed by isobaric tags for relative and absolute quantitation (iTRAQ)-based liquid chromatography-tandem mass spectrometry (LC-MS/MS). In the clinical cohort, archived CSF samples obtained through routine external ventricular drainage within 24 h after surgery were analyzed in adults with first-ever spontaneous ICH (n = 41). HPX and vitamin D-binding protein(GC/VDBP) were quantified by enzyme-linked immunosorbent assay (ELISA). Secondary sepsis was identified using an operationalized Sepsis-3 framework after excluding infection or sepsis at admission.
RESULTS: In the animal model, ICH + CLP was associated with worse early survival than ICH alone (log-rank χ2 = 12.25, p = 0.0005), and HPX was identified as a candidate protein linked to the combined hemorrhage-sepsis condition. In the clinical cohort, CSF-HPX was positively associated with hematoma volume and was higher in patients who subsequently developed secondary sepsis than in those who did not (558.17 [279.48-773.39] ng/mL vs. 305.99 [218.77-354.24] ng/mL, p = 0.006). This association remained significant after adjustment (adjusted odds ratio (OR) 1.016, 95% confidence interval (CI) 1.002-1.031; p = 0.023), and CSF-HPX showed exploratory discriminatory value for secondary sepsis (area under the curve (AUC) 0.888). Higher CSF-HPX levels were also associated with in-hospital mortality, although this finding should be interpreted cautiously.
CONCLUSIONS: CSF-HPX may be a candidate biomarker associated with hemorrhage burden and risk of secondary sepsis after ICH. These findings are exploratory and require validation in larger prospective studies.
参考来源
- Xie T, Feng W, He Y, et al. Cerebrospinal Fluid Hemopexin as a Candidate Biomarker for Secondary Sepsis and In-Hospital Outcome After Spontaneous Intracerebral Hemorrhage: An Exploratory Translational Proteomics Study. Neurocrit Care. 2026. PMID: 42573709. doi:10.1007/s12028-026-02630-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。